HKSE · 2219.HK
Chaoju Eye Care Holdings Limited
HK$2.38+HK$0.02 (+0.64%)
Chaoju Eye Care Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 24.36% below the high.
Loading market information…
HKSE · 2407.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:03 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Gaush Meditech Ltd’s quoted price sits in the lower half of its reported 52-week range, 59.96% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Gaush Meditech Ltd’s forward annual dividend is HK$0.30 per share, paid annual. The forward yield is 7.5% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Gaush Meditech Ltd’s next earnings report is currently expected on Apr 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Gaush Meditech Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$2.38+HK$0.02 (+0.64%)
Chaoju Eye Care Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 24.36% below the high.
HK$0.93-HK$0.01 (-0.54%)
Rici Healthcare Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 25.4% below the high.
HK$8.98-HK$0.03 (-0.28%)
Beijing Airdoc Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.91% below the high.
HK$0.90+HK$0.01 (+0.56%)
Kindstar Globalgene Technology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.82% below the high.
HK$2.20HK$0.00 (0.0%)
EuroEyes International Eye Clinic Limited’s quoted price sits in the lower half of its reported 52-week range, 34.33% below the high.
HK$0.97HK$0.00 (0.0%)
Brii Biosciences Limited’s quoted price sits in the lower half of its reported 52-week range, 48.95% below the high.
HK$3.80HK$0.00 (0.0%)
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
HK$1.06HK$0.00 (0.0%)
Lee's Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 46.72% below the high.
